[Source: PRNewswire] – NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product. Under the agreement, NeoStem will investigate the effects of Homspera(R), ImmuneRegen’s lead drug candidate, which has been shown to enhance stem cell activity, in combination with NeoStem’s VSEL(TM) technology. Very small embryonic-like stem cells are a population of stem cells found in the bone marrow that can be mobilized and subsequently harvested from the peripheral blood of adults.
NeoStem, Inc. and ImmuneRegen BioSciences(R) announce a collaborative agreement
April 22, 2010